Navigation Links
CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009
Date:8/14/2009

With its Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration (FDA), Immunovative Therapies, Ltd. (ITL) announced that Phase I/II clinical trials of its experimental CryoStim™ cancer vaccine product for the treatment of advanced metastatic solid tumors will begin September, 2009. CryoStimTM is an individualized cancer vaccine that is made inside the body by combining the experimental AlloStimTM drug with the killing of a selected tumor by the minimally invasive procedure called cryoablation. AlloStimTM contains living immune cells attached to microbeads designed to stimulate and direct the human immune system to directly kill cancer cells wherever they reside in the body. Phase I/II clinical trials will be conducted at its new clinical research subsidiary in Carlsbad, California.

San Diego, California (PRWEB) -- Immunovative Therapies Ltd. (http://www.immunovative.co.il.) has announced that its CryoStim™ experimental product has been cleared by the FDA to begin human clinical trials. Immunovative Therapies, Ltd. experimental products are based upon “Mirror Effect™” technology (patents issued and pending) which is designed to provide the same anti-tumor effect that has been proven to be curative in allogeneic bone marrow transplant (BMT) procedures without the lethal toxicity or need for a matched donor.

Immunotherapy is a new modality for cancer treatment which holds great promise for becoming a curative therapy with minimal toxicity. It works together with or replaces current treatment methods. The human immune system is capable of seeking out and destroying cancers cells wherever they reside in the body. Harnessing the power of the immune system holds the greatest potential for winning the battle against cancer.

“CryoStim™ represents a completely novel approach for therapeutic cancer design,” says Michael Har-Noy PhD, CEO and Chief Technical Officer. “Current therapies are not capable of eliminating every last cancer cell in the body and thus tumor recurrence is a common problem. If our experimental therapy is successful it would be possible to not only eliminate every last tumor cells, but also for the immune system to remember the tumor in order to prevent recurrence.”

Details about this cancer vaccine trial can be found at www.immunocare.net and at clinicaltrials.gov: NCT00861107. View complete details on products, trial and scientific literature at the company website.

About Immunovative:
Immunovative Therapies, Ltd. (ITL) is an Israeli-based biopharmaceutical company with US facilities in Carlsbad, California. Founded in May 2004 with financial support from Israel’s Office of the Chief Scientist, ITL is a graduate of the Misgav Venture Accelerator, a member of the world renowned Israel technological incubator program. The company was the Misgav Venture Accelerator’s candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate bioengineered living immune cells as the active ingredients for treatment of cancer, autoimmune and infectious disease.

Contact:
Michael Berger MD at 760-444-9040

In the Pacific Northwest contact Alan F. Hall JD at 425-774-9566

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2750204.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination ... are complicated and require expert user knowledge. In a live webinar on April ... the simplified, yet highly accurate, determination of sodium. , It has long been ...
(Date:3/27/2017)... Irvine, CA (PRWEB) , ... March 27, 2017 ... ... company has entered a settlement agreement to resolve the pending litigation between itself ... Court for the District of Utah). , “I am thrilled to announce that ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Harris Communications, Inc., ... hearing, is bringing its latest products to the Deaf Seniors of America Conference, April ... the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and to ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Microplate Instrumentation ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:3/24/2017)... 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today disclosed ... Term Sheet (the "Definitive Financing") it entered into ... Company,s stockholders, who are referred to in the ... 8-K filed with the Securities and Exchange Commission. ...
Breaking Medicine Technology: